Skip to main content
Top
Published in: Langenbeck's Archives of Surgery 7/2017

01-11-2017 | ORIGINAL ARTICLE

Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm

Authors: Joaquín Gómez-Ramírez, Radu Mihai

Published in: Langenbeck's Archives of Surgery | Issue 7/2017

Login to get access

Abstract

In recent years, there has been increasing interest in understanding the implications of diagnosing normocalcaemic primary hyperparathyroidism (nPHPT). Many patients hope that nPHPT might explain some of their symptoms, but surgeons hesitate to offer treatment to patients whose calcium levels are normal but whose parathyroid hormone (PTH) levels are elevated in the absence of secondary causes of hyperparathyroidism. This potential new diagnosis is not well understood and may lead to inappropriate investigation and possible unnecessary operations. However, because a significant number of patients with nPHPT progress to hypercalcaemic primary hyperparathyroidism (PHPT), some consider nPHPT to be an early or mild form of hypercalcaemia. Rather than being an indolent disease, nPHPT was reported to be associated with systemic complications similar to ‘classical’ PHPT, and hence there is growing interest to understand who should be offered surgical treatment and who should be monitored. Further standardisation of diagnostic definition, associated complications, patient selection, surgical management and long-term outcomes are necessary. The recommendations outlined in this review are based on limited evidence from non-randomised cohort studies and expert opinion.
Literature
1.
go back to reference Sitges-Serra A, Bergenfelz A (2007) Clinical update: sporadic primary hyperparathyroidism. Lancet (London, England) 370(9586):468–470CrossRef Sitges-Serra A, Bergenfelz A (2007) Clinical update: sporadic primary hyperparathyroidism. Lancet (London, England) 370(9586):468–470CrossRef
2.
go back to reference Marcocci C, Cetani F (2011) Clinical practice. Primary hyperparathyroidism. N Engl J Med 365(25):2389–2397CrossRefPubMed Marcocci C, Cetani F (2011) Clinical practice. Primary hyperparathyroidism. N Engl J Med 365(25):2389–2397CrossRefPubMed
3.
go back to reference Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR (2009) Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94(2):351–365CrossRefPubMedPubMedCentral Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR (2009) Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94(2):351–365CrossRefPubMedPubMedCentral
4.
go back to reference Wills MR, Pak CY, Hammond WG, Bartter FC (1969) Normocalcemic primary hyperparathyroidism. Am J Med 47(3):384–391CrossRefPubMed Wills MR, Pak CY, Hammond WG, Bartter FC (1969) Normocalcemic primary hyperparathyroidism. Am J Med 47(3):384–391CrossRefPubMed
5.
go back to reference Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M (2012) Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine 42(3):764–766CrossRefPubMed Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M (2012) Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine 42(3):764–766CrossRefPubMed
6.
go back to reference Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S (1997) Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121(3):287–294CrossRefPubMed Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S (1997) Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121(3):287–294CrossRefPubMed
7.
go back to reference Marques TF, Vasconcelos R, Diniz E, Rego D, Griz L, Bandeira F (2011) Normocalcaemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq Bras Endocrinol Metabol 55(5):314–317CrossRefPubMedPubMedCentral Marques TF, Vasconcelos R, Diniz E, Rego D, Griz L, Bandeira F (2011) Normocalcaemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq Bras Endocrinol Metabol 55(5):314–317CrossRefPubMedPubMedCentral
8.
go back to reference Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM et al (2013) Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 98(7):2734–2741CrossRefPubMedPubMedCentral Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM et al (2013) Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 98(7):2734–2741CrossRefPubMedPubMedCentral
9.
go back to reference Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92(8):3001–3005CrossRefPubMed Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92(8):3001–3005CrossRefPubMed
10.
go back to reference Tuna MM, Caliskan M, Unal M, Demirci T, Dogan BA, Kucukler K et al (2016) Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J Bone Miner Metab 34(3):331–335CrossRefPubMed Tuna MM, Caliskan M, Unal M, Demirci T, Dogan BA, Kucukler K et al (2016) Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J Bone Miner Metab 34(3):331–335CrossRefPubMed
11.
go back to reference Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F (2012) Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012:128352CrossRefPubMedPubMedCentral Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F (2012) Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012:128352CrossRefPubMedPubMedCentral
12.
go back to reference Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E et al (2013) Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 98(8):3213–3220CrossRefPubMed Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E et al (2013) Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 98(8):3213–3220CrossRefPubMed
13.
go back to reference Koumakis E, Souberbielle JC, Payet J, Sarfati E, Borderie D, Kahan A et al (2014) Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism. Osteoporos Int 25(7):1963–1968CrossRefPubMed Koumakis E, Souberbielle JC, Payet J, Sarfati E, Borderie D, Kahan A et al (2014) Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism. Osteoporos Int 25(7):1963–1968CrossRefPubMed
14.
go back to reference Silverberg SJ, Bilezikian JP (2003) “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J Clin Endocrinol Metab 88(11):5348–5352CrossRefPubMed Silverberg SJ, Bilezikian JP (2003) “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J Clin Endocrinol Metab 88(11):5348–5352CrossRefPubMed
15.
go back to reference Siprova H, Frysak Z, Soucek M (2016) Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr Pract 22(3):294–301CrossRefPubMed Siprova H, Frysak Z, Soucek M (2016) Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr Pract 22(3):294–301CrossRefPubMed
16.
go back to reference Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N (2004) Characterization of normocalcemic primary hyperparathyroidism. Am J Med 117(11):861–863CrossRefPubMed Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N (2004) Characterization of normocalcemic primary hyperparathyroidism. Am J Med 117(11):861–863CrossRefPubMed
17.
go back to reference Yener Ozturk F, Erol S, Canat MM, Karatas S, Kuzu I, Dogan Cakir S et al (2016) Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr J 63(2):111–118CrossRefPubMed Yener Ozturk F, Erol S, Canat MM, Karatas S, Kuzu I, Dogan Cakir S et al (2016) Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr J 63(2):111–118CrossRefPubMed
18.
go back to reference Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H et al (2015) Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 100(6):2420–2424CrossRefPubMed Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H et al (2015) Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 100(6):2420–2424CrossRefPubMed
20.
go back to reference Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C et al (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3561–3569CrossRefPubMedPubMedCentral Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C et al (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3561–3569CrossRefPubMedPubMedCentral
21.
go back to reference Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM (1988) Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 67(6):1294–1298CrossRefPubMed Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM (1988) Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 67(6):1294–1298CrossRefPubMed
22.
go back to reference Maruani G, Hertig A, Paillard M, Houillier P (2003) Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88(10):4641–4648CrossRefPubMed Maruani G, Hertig A, Paillard M, Houillier P (2003) Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88(10):4641–4648CrossRefPubMed
23.
go back to reference Balsa JA, Botella-Carretero JI, Peromingo R, Zamarron I, Arrieta F, Munoz-Malo T et al (2008) Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Investig 31(10):845–850CrossRef Balsa JA, Botella-Carretero JI, Peromingo R, Zamarron I, Arrieta F, Munoz-Malo T et al (2008) Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Investig 31(10):845–850CrossRef
24.
go back to reference Selby PL, Davies M, Adams JE, Mawer EB (1999) Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res Off J Am Soc Bone Miner Res 14(4):652–657CrossRef Selby PL, Davies M, Adams JE, Mawer EB (1999) Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res Off J Am Soc Bone Miner Res 14(4):652–657CrossRef
25.
go back to reference Lavryk OA, Siperstein AE (2017) Use of calcium and parathyroid hormone nomogram to distinguish between atypical primary hyperparathyroidism and normal patients. World J Surg 41(1):122–128CrossRefPubMed Lavryk OA, Siperstein AE (2017) Use of calcium and parathyroid hormone nomogram to distinguish between atypical primary hyperparathyroidism and normal patients. World J Surg 41(1):122–128CrossRefPubMed
26.
go back to reference Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3570–3579CrossRefPubMed Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3570–3579CrossRefPubMed
27.
go back to reference Nordenstrom E, Katzman P, Bergenfelz A (2011) Biochemical diagnosis of primary hyperparathyroidism: analysis of the sensitivity of total and ionized calcium in combination with PTH. Clin Biochem 44(10–11):849–852CrossRefPubMed Nordenstrom E, Katzman P, Bergenfelz A (2011) Biochemical diagnosis of primary hyperparathyroidism: analysis of the sensitivity of total and ionized calcium in combination with PTH. Clin Biochem 44(10–11):849–852CrossRefPubMed
28.
go back to reference Ong GS, Walsh JP, Stuckey BG, Brown SJ, Rossi E, Ng JL et al (2012) The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab 97(9):3138–3145CrossRefPubMed Ong GS, Walsh JP, Stuckey BG, Brown SJ, Rossi E, Ng JL et al (2012) The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab 97(9):3138–3145CrossRefPubMed
29.
go back to reference Wade TJ, Yen TW, Amin AL, Wang TS (2012) Surgical management of normocalcemic primary hyperparathyroidism. World J Surg 36(4):761–766CrossRefPubMed Wade TJ, Yen TW, Amin AL, Wang TS (2012) Surgical management of normocalcemic primary hyperparathyroidism. World J Surg 36(4):761–766CrossRefPubMed
30.
go back to reference Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911–1930CrossRefPubMed Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911–1930CrossRefPubMed
31.
go back to reference KDIGO (2009) Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1–130 KDIGO (2009) Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1–130
32.
33.
go back to reference Souberbielle JC, Cavalier E, Cormier C (2015) How to manage an isolated elevated PTH? Ann Endocrinol 76(2):134–141CrossRef Souberbielle JC, Cavalier E, Cormier C (2015) How to manage an isolated elevated PTH? Ann Endocrinol 76(2):134–141CrossRef
34.
go back to reference Carneiro-Pla DM, Irvin GL 3rd, Chen H (2007) Consequences of parathyroidectomy in patients with “mild” sporadic primary hyperparathyroidism. Surgery 142(6):795–799 discussion 9.e1–2CrossRefPubMed Carneiro-Pla DM, Irvin GL 3rd, Chen H (2007) Consequences of parathyroidectomy in patients with “mild” sporadic primary hyperparathyroidism. Surgery 142(6):795–799 discussion 9.e1–2CrossRefPubMed
35.
go back to reference Lim JY, Herman MC, Bubis L, Epelboym I, Allendorf JD, Chabot JA et al (2017) Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism. Surgery 161(1):70–77CrossRefPubMed Lim JY, Herman MC, Bubis L, Epelboym I, Allendorf JD, Chabot JA et al (2017) Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism. Surgery 161(1):70–77CrossRefPubMed
36.
go back to reference Goldfarb M, Gondek S, Irvin GL 3rd, Lew JI (2011) Normocalcemic parathormone elevation after successful parathyroidectomy: long-term analysis of parathormone variations over 10 years. Surgery 150(6):1076–1084CrossRefPubMed Goldfarb M, Gondek S, Irvin GL 3rd, Lew JI (2011) Normocalcemic parathormone elevation after successful parathyroidectomy: long-term analysis of parathormone variations over 10 years. Surgery 150(6):1076–1084CrossRefPubMed
37.
go back to reference Carsello CB, Yen TW, Wang TS (2012) Persistent elevation in serum parathyroid hormone levels in normocalcemic patients after parathyroidectomy: does it matter? Surgery 152(4):575–581 discussion 81–3CrossRefPubMed Carsello CB, Yen TW, Wang TS (2012) Persistent elevation in serum parathyroid hormone levels in normocalcemic patients after parathyroidectomy: does it matter? Surgery 152(4):575–581 discussion 81–3CrossRefPubMed
38.
go back to reference Stuart HC, Harvey A, Pasieka JL (2014) Normocalcemic hyperparathyroidism: preoperatively a disease, postoperatively cured? Am J Surg 207(5):673–680 discussion 80–1CrossRefPubMed Stuart HC, Harvey A, Pasieka JL (2014) Normocalcemic hyperparathyroidism: preoperatively a disease, postoperatively cured? Am J Surg 207(5):673–680 discussion 80–1CrossRefPubMed
Metadata
Title
Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm
Authors
Joaquín Gómez-Ramírez
Radu Mihai
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
Langenbeck's Archives of Surgery / Issue 7/2017
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-017-1617-2

Other articles of this Issue 7/2017

Langenbeck's Archives of Surgery 7/2017 Go to the issue